{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:31:59Z","timestamp":1786995119906,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008238","name":"Hebei Province Department of Science And Technology","doi-asserted-by":"publisher","award":["GL2011 -51"],"award-info":[{"award-number":["GL2011 -51"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008238","name":"Hebei Province Department of Science And Technology","doi-asserted-by":"publisher","award":["16397733D"],"award-info":[{"award-number":["16397733D"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008238","name":"Hebei Province Department of Science And Technology","doi-asserted-by":"publisher","award":["G2018050"],"award-info":[{"award-number":["G2018050"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008238","name":"Hebei Province Department of Science And Technology","doi-asserted-by":"publisher","award":["20377704D"],"award-info":[{"award-number":["20377704D"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.numecd.2021.02.006","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T05:43:36Z","timestamp":1613367816000},"page":"1365-1374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Yaling","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2021.02.006_bib1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2021.02.006_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcp.2015.09.005","article-title":"SGLT2 inhibitors","volume":"101","author":"Dardi","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2021.02.006_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/dom.13987","article-title":"Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY","volume":"22","author":"Rhee","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.02.006_bib4","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2021.02.006_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.numecd.2021.02.006_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.02.006_bib7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.02.006_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.02.006_bib9","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s13300-019-0674-7","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in east asians with type 2 diabetes: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2021.02.006_bib10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.02.006_bib11","doi-asserted-by":"crossref","first-page":"m1584","DOI":"10.1136\/bmj.m1584","article-title":"SGLT2 inhibitors and kidney outcomes in the real world","volume":"369","author":"Smith","year":"2020","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2021.02.006_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.numecd.2021.02.006_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4158\/1934-2403-24.1.126","article-title":"Re: diabetic ketoacidosis in patients with type 2 diabetes on sglt-2 inhibitors: an ongoing concern","volume":"24","author":"Bell","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1016\/j.numecd.2021.02.006_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.numecd.2021.02.006_bib15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.numecd.2021.02.006_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2021.02.006_bib17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.02.006_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.02.006_bib19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.02.006_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2021.02.006_bib21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.02.006_bib22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.02.006_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.numecd.2021.02.006_bib24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2021.02.006_bib25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.02.006_bib26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.numecd.2021.02.006_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.numecd.2021.02.006_bib28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/dom.14041","article-title":"Safety of dapagliflozin in a broad population of patients with type 2 diabetes: analyses from the DECLARE-TIMI 58 study","volume":"22","author":"Cahn","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.02.006_bib29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.numecd.2021.02.006_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2021.02.006_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.02.006_bib32","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.numecd.2021.02.006_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14740338.2020.1764532","article-title":"Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment","volume":"19","author":"Sampani","year":"2020","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.numecd.2021.02.006_bib34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.02.006_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S2213-8587(19)30387-0","article-title":"SGLT2 inhibitors to prevent diabetic kidney disease","volume":"8","author":"Fioretto","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2021.02.006_bib36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/j.ajkd.2019.05.009","article-title":"Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors","volume":"74","author":"Bakris","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.numecd.2021.02.006_bib37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.02.006_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials","volume":"130","author":"Monami","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2021.02.006_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.02.006_bib40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2021.02.006_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.numecd.2021.02.006_bib42","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.02.006_bib43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.numecd.2021.02.006_bib44","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/dom.14091","article-title":"The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial","volume":"22","author":"Arnott","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.02.006_bib45","doi-asserted-by":"crossref","first-page":"115254","DOI":"10.1016\/j.bone.2020.115254","article-title":"Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone","volume":"133","author":"Thrailkill","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.numecd.2021.02.006_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-017-0125-x","article-title":"Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes","volume":"18","author":"Kawasoe","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.numecd.2021.02.006_bib47","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Phys Rep"},{"key":"10.1016\/j.numecd.2021.02.006_bib48","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.02.006_bib49","doi-asserted-by":"crossref","first-page":"107587","DOI":"10.1016\/j.jdiacomp.2020.107587","article-title":"Effects of sodium glucose co-transporter 2 inhibitors on genital infections in female patients with type 2 diabetes mellitus- Real world data analysis","volume":"34","author":"Nakhleh","year":"2020","journal-title":"J Diabet Complicat"},{"key":"10.1016\/j.numecd.2021.02.006_bib50","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:09:01Z","timestamp":1778558941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0939475321000557"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.02.006","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}